1-20 of 54
Jaap Verweij
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla, Anthony W. Tolcher, Patricia M. LoRusso, Joseph P. Eder, Martin Gutierrez, Kumar Sankhala, Prabhu Rajagopalan, Isabelle Genvresse, Simon Langer, Ron H.J. Mathijssen, Jaap Verweij, Ingmar Bruns, Martijn P. Lolkema
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2969.
https://doi.org/10.1158/1078-0432.CCR-22-1792
Published: 01 July 2022
View article titled, Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Open the PDF for Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation in another window
Journal Articles

A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla, Anthony W. Tolcher, Patricia M. LoRusso, Joseph P. Eder, Martin Gutierrez, Kumar Sankhala, Prabhu Rajagopalan, Isabelle Genvresse, Simon Langer, Ron H.J. Mathijssen, Jaap Verweij, Ingmar Bruns, Martijn P. Lolkema
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6366–6375.
https://doi.org/10.1158/1078-0432.CCR-20-4185
Published: 01 December 2021
View article titled, A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Open the PDF for A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation in another window
Includes: Supplementary data
Journal Articles

Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

Victor Moreno García, David Olmos, Carlos Gomez-Roca, Philippe A. Cassier, Rafael Morales-Barrera, Gianluca Del Conte, Elisa Gallerani, Andre T. Brunetto, Patrick Schöffski, Silvia Marsoni, Jan H.M. Schellens, Nicolas Penel, Emile Voest, Jeffrey Evans, Ruth Plummer, Richard H. Wilson, Jean Charles Soria, Josep Tabernero, Jaap Verweij, Stan B. Kaye
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5663–5671.
https://doi.org/10.1158/1078-0432.CCR-14-0719
Published: 13 November 2014
View article titled, Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study
Open the PDF for Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study in another window
Includes: Supplementary data
Journal Articles

A Pharmacogenetic Predictive Model for Paclitaxel Clearance Based on the DMET Platform

Anne-Joy M. de Graan, Laure Elens, Marcel Smid, John W. Martens, Alex Sparreboom, Annemieke J.M. Nieuweboer, Lena E. Friberg, Samira Elbouazzaoui, Erik A.C. Wiemer, Bronno van der Holt, Jaap Verweij, Ron H.N. van Schaik, Ron H.J. Mathijssen
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (18): 5210–5217.
https://doi.org/10.1158/1078-0432.CCR-13-0487
Published: 16 September 2013
View article titled, A Pharmacogenetic Predictive Model for Paclitaxel Clearance Based on the DMET Platform
Open the PDF for A Pharmacogenetic Predictive Model for Paclitaxel Clearance Based on the DMET Platform in another window
Journal Articles

CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

Anne-Joy M. de Graan, Laure Elens, Jason A. Sprowl, Alex Sparreboom, Lena E. Friberg, Bronno van der Holt, Pleun J. de Raaf, Peter de Bruijn, Frederike K. Engels, Ferry A.L.M. Eskens, Erik A.C. Wiemer, Jaap Verweij, Ron H.J. Mathijssen, Ron H.N. van Schaik
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (12): 3316–3324.
https://doi.org/10.1158/1078-0432.CCR-12-3786
Published: 13 June 2013
View article titled, <em>CYP3A4*22</em> Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity
Open the PDF for <em>CYP3A4*22</em> Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity in another window
Includes: Supplementary data
Journal Articles

A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

Karel Eechoute, Martin N. Fransson, An K. Reyners, Floris A. de Jong, Alex Sparreboom, Winette T.A. van der Graaf, Lena E. Friberg, Gaia Schiavon, Erik A.C. Wiemer, Jaap Verweij, Walter J. Loos, Ron H.J. Mathijssen, Ugo De Giorgi
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (20): 5780–5787.
https://doi.org/10.1158/1078-0432.CCR-12-0490
Published: 14 October 2012
View article titled, A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients
Open the PDF for A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients in another window
Includes: Supplementary data
Journal Articles

Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era

Philippe A. Cassier, Elena Fumagalli, Piotr Rutkowski, Patrick Schöffski, Martine Van Glabbeke, Maria Debiec-Rychter, Jean-François Emile, Florence Duffaud, Javier Martin-Broto, Bruno Landi, Antoine Adenis, François Bertucci, Emmanuelle Bompas, Olivier Bouché, Serge Leyvraz, Ian Judson, Jaap Verweij, Paolo Casali, Jean-Yves Blay, Peter Hohenberger, for the European Organisation for Research and Treatment of Cancer
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (16): 4458–4464.
https://doi.org/10.1158/1078-0432.CCR-11-3025
Published: 14 August 2012
View article titled, Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
Open the PDF for Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era in another window
Includes: Supplementary data
Journal Articles

Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy

Anne-Joy M. de Graan, Walter J. Loos, Lena E. Friberg, Sharyn D. Baker, Jessica M. van der Bol, Leni van Doorn, Erik A.C. Wiemer, Bronno van der Holt, Jaap Verweij, Ron H.J. Mathijssen
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (16): 4425–4432.
https://doi.org/10.1158/1078-0432.CCR-12-0728
Published: 14 August 2012
View article titled, Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy
Open the PDF for Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy in another window
Includes: Supplementary data
Journal Articles

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

George D. Demetri, Christopher R. Garrett, Patrick Schöffski, Manisha H. Shah, Jaap Verweij, Serge Leyvraz, Herbert I. Hurwitz, Antonio Lopez Pousa, Axel Le Cesne, David Goldstein, Luis Paz-Ares, Jean-Yves Blay, Grant A. McArthur, Qiang (Casey) Xu, Xin Huang, Charles S. Harmon, Vanessa Tassell, Darrel P. Cohen, Paolo G. Casali
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (11): 3170–3179.
https://doi.org/10.1158/1078-0432.CCR-11-3005
Published: 31 May 2012
View article titled, Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure
Open the PDF for Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure in another window
Includes: Supplementary data
Journal Articles

A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors

Udai Banerji, Leni van Doorn, Dionysis Papadatos-Pastos, Rebecca Kristeleit, Phillip Debnam, Matthew Tall, Adam Stewart, Florence Raynaud, Michelle Dawn Garrett, Martin Toal, Leon Hooftman, Johann Sebastian De Bono, Jaap Verweij, Ferry ALM Eskens
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (9): 2687–2694.
https://doi.org/10.1158/1078-0432.CCR-11-3165
Published: 30 April 2012
View article titled, A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
Open the PDF for A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development

George Poste, David P. Carbone, David R. Parkinson, Jaap Verweij, Stephen M. Hewitt, J. Milburn Jessup
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1515–1523.
https://doi.org/10.1158/1078-0432.CCR-11-2206
Published: 14 March 2012
View article titled, Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development
Open the PDF for Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development in another window
Journal Articles

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors

Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M. Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, Jaap Verweij
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (22): 7156–7163.
https://doi.org/10.1158/1078-0432.CCR-11-0411
Published: 14 November 2011
View article titled, Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
Open the PDF for Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

Karel Eechoute, Alex Sparreboom, Herman Burger, Ryan M. Franke, Gaia Schiavon, Jaap Verweij, Walter J. Loos, Erik A.C. Wiemer, Ron H.J. Mathijssen
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (3): 406–415.
https://doi.org/10.1158/1078-0432.CCR-10-2250
Published: 01 February 2011
View article titled, Drug Transporters and Imatinib Treatment: Implications for Clinical Practice
Open the PDF for Drug Transporters and Imatinib Treatment: Implications for Clinical Practice in another window
Journal Articles

Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study

Frederike K. Engels, Walter J. Loos, Jessica M. van der Bol, Peter de Bruijn, Ron H.J. Mathijssen, Jaap Verweij, Ron A.A. Mathot
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (2): 353–362.
https://doi.org/10.1158/1078-0432.CCR-10-1636
Published: 16 January 2011
View article titled, Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study
Open the PDF for Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study in another window
Journal Articles

A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan

Jessica M. van der Bol, Ron H.J. Mathijssen, Geert-Jan M. Creemers, André S.Th. Planting, Walter J. Loos, Erik A.C. Wiemer, Lena E. Friberg, Jaap Verweij, Alex Sparreboom, Floris A. de Jong
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (2): 736–742.
https://doi.org/10.1158/1078-0432.CCR-09-1526
Published: 14 January 2010
View article titled, A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan
Open the PDF for A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan in another window
Includes: Supplementary data
Journal Articles

Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure

Samuel E. DePrimo, Xin Huang, Martin E. Blackstein, Christopher R. Garrett, Charles S. Harmon, Patrick Schöffski, Manisha H. Shah, Jaap Verweij, Charles M. Baum, George D. Demetri
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (18): 5869–5877.
https://doi.org/10.1158/1078-0432.CCR-08-2480
Published: 14 September 2009
View article titled, Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure
Open the PDF for Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure in another window
Includes: Supplementary data
Journal Articles

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

Constantijne H. Mom, Jaap Verweij, Corina N.A.M. Oldenhuis, Jourik A. Gietema, Norma Lynn Fox, Renée Miceli, Ferry A.L.M. Eskens, Walter J. Loos, Elisabeth G.E. de Vries, Stefan Sleijfer
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (17): 5584–5590.
https://doi.org/10.1158/1078-0432.CCR-09-0996
Published: 31 August 2009
View article titled, Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
Open the PDF for Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study in another window
Includes: Supplementary data
Journal Articles

Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors

Salvatore Romeo, Maria Debiec-Rychter, Martine Van Glabbeke, Heidi Van Paassen, Paola Comite, Ronald Van Eijk, Jan Oosting, Jaap Verweij, Philippe Terrier, Ulrike Schneider, Raf Sciot, Jean Yves Blay, Pancras C.W. Hogendoorn, on behalf of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (12): 4191–4198.
https://doi.org/10.1158/1078-0432.CCR-08-3297
Published: 15 June 2009
View article titled, Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors
Open the PDF for Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors in another window
Includes: Supplementary data
Journal Articles

Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC

Nielka van Erp, Hans Gelderblom, Martine van Glabbeke, Allan Van Oosterom, Jaap Verweij, Henk-Jan Guchelaar, Maria Debiec-Rychter, Bin Peng, Jean-Yves Blay, Ian Judson
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (24): 8308–8313.
https://doi.org/10.1158/1078-0432.CCR-08-1303
Published: 15 December 2008
View article titled, Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC
Open the PDF for Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC in another window
Journal Articles

Interaction of Cisplatin with the Human Organic Cation Transporter 2

Kelly K. Filipski, Walter J. Loos, Jaap Verweij, Alex Sparreboom
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3875–3880.
https://doi.org/10.1158/1078-0432.CCR-07-4793
Published: 16 June 2008
View article titled, Interaction of Cisplatin with the Human Organic Cation Transporter 2
Open the PDF for Interaction of Cisplatin with the Human Organic Cation Transporter 2 in another window